Stayble Therapeutics AB (publ) (STO:STABL)
0.2050
-0.0100 (-4.65%)
Inactive · Last trade price on Jun 2, 2026
Stayble Therapeutics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.1 | 2.45 | 2.2 | 14.08 | 12.85 | 37.47 |
Cash & Short-Term Investments | 1.1 | 2.45 | 2.2 | 14.08 | 12.85 | 37.47 |
Cash Growth | -57.12% | 11.70% | -84.41% | 9.60% | -65.71% | 244.77% |
Other Receivables | 0.41 | 0.23 | 0.13 | 0.25 | 0.61 | 0.45 |
Receivables | 0.41 | 0.23 | 0.13 | 0.25 | 0.61 | 0.45 |
Prepaid Expenses | 0.51 | 0.29 | 1.28 | 1.72 | 0.04 | 0.08 |
Total Current Assets | 2.02 | 2.97 | 3.61 | 16.05 | 13.5 | 37.99 |
Long-Term Investments | - | - | - | - | - | 0 |
Long-Term Deferred Charges | 1.3 | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 |
Total Assets | 3.32 | 8.62 | 9.26 | 21.7 | 19.15 | 43.64 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.44 | 0.23 | 0.27 | 2.55 | 1.04 | 0.43 |
Accrued Expenses | 0.39 | 0.36 | 1.07 | 1.56 | 1.82 | 2.2 |
Other Current Liabilities | 0.58 | 0.26 | 0.2 | 0.23 | 0.15 | 0.35 |
Total Current Liabilities | 1.41 | 0.85 | 1.53 | 4.34 | 3.02 | 2.98 |
Long-Term Debt | - | 0.85 | 0.85 | 0.85 | 0.85 | 0.85 |
Other Long-Term Liabilities | 0.85 | - | - | - | - | - |
Total Liabilities | 2.26 | 1.7 | 2.38 | 5.19 | 3.87 | 3.83 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 8.37 | 8.37 | 5.68 | 4.12 | 1.8 | 1.8 |
Additional Paid-In Capital | - | 3.56 | - | - | 36.08 | 48.18 |
Retained Earnings | -9.23 | -6.93 | -0.73 | 10.46 | -24.53 | -12.09 |
Comprehensive Income & Other | 1.92 | 1.92 | 1.92 | 1.92 | 1.92 | 1.92 |
Shareholders' Equity | 1.06 | 6.92 | 6.87 | 16.51 | 15.28 | 39.81 |
Total Liabilities & Equity | 3.32 | 8.62 | 9.26 | 21.7 | 19.15 | 43.64 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | 0.85 | 0.85 | 0.85 | 0.85 | 0.85 |
Net Cash (Debt) | 1.1 | 1.6 | 1.35 | 13.23 | 12 | 36.62 |
Net Cash Growth | -35.93% | 19.09% | -89.83% | 10.28% | -67.24% | 272.78% |
Net Cash Per Share | - | 0.03 | 0.04 | 0.51 | 0.87 | 2.64 |
Filing Date Shares Outstanding | - | 64.36 | 51.72 | 31.72 | 13.85 | 13.85 |
Total Common Shares Outstanding | - | 64.36 | 43.72 | 31.72 | 13.85 | 13.85 |
Working Capital | 0.61 | 2.12 | 2.07 | 11.71 | 10.48 | 35.01 |
Book Value Per Share | - | 0.11 | 0.16 | 0.52 | 1.10 | 2.87 |
Tangible Book Value | 1.06 | 6.92 | 6.87 | 16.51 | 15.28 | 39.81 |
Tangible Book Value Per Share | - | 0.11 | 0.16 | 0.52 | 1.10 | 2.87 |